Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR – Get Free Report)’s share price gapped up prior to trading on Thursday. The stock had previously closed at $9.65, but opened at $10.57. Pharming Group shares last traded at $10.69, with a volume of 6,499 shares changing hands.
Analysts Set New Price Targets
A number of research analysts have weighed in on PHAR shares. Wall Street Zen upgraded shares of Pharming Group to a “hold” rating in a research note on Saturday. Canaccord Genuity Group set a $38.00 price target on shares of Pharming Group in a research report on Wednesday, September 23rd. Zacks Research downgraded Pharming Group from a “hold” rating to a “strong sell” rating in a research report on Friday, July 31st. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Pharming Group in a report on Friday, August 7th. Finally, Oppenheimer reiterated an “outperform” rating on shares of Pharming Group in a research report on Thursday, July 30th. Three equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $38.67.
View Our Latest Stock Analysis on Pharming Group
Pharming Group Trading Up 5.0%
The firm’s 50-day simple moving average is $10.67 and its 200-day simple moving average is $12.62. The firm has a market capitalization of $792.74 million, a P/E ratio of 93.33 and a beta of -0.05. The company has a quick ratio of 2.31, a current ratio of 3.01 and a debt-to-equity ratio of 0.34.
Pharming Group (NASDAQ:PHAR – Get Free Report) last released its earnings results on Thursday, July 30th. The company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.04). Pharming Group had a net margin of 2.51% and a return on equity of 3.40%. Analysts anticipate that Pharming Group N.V. Sponsored ADR will post 0.22 EPS for the current year.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Pharming Group stock. MAC Alpha Capital Management LP bought a new stake in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 2,148,144 shares of the company’s stock, valued at approximately $29,838,000. Pharming Group comprises approximately 6.0% of MAC Alpha Capital Management LP’s portfolio, making the stock its 2nd largest position. MAC Alpha Capital Management LP owned about 3.03% of Pharming Group as of its most recent SEC filing. 0.03% of the stock is currently owned by institutional investors.
Pharming Group Company Profile
Pharming Group N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and operates internationally, serving patients and healthcare providers in North America, Europe and other selected markets.
Pharming’s principal product is Ruconest, a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially serious swelling. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.
Featured Articles
- Five stocks we like better than Pharming Group
- Amex Stock Slides on Job Cuts, But the Real Story Is Macro
- Chefs’ Warehouse Has Rallied 76%—Can the Stock Keep Climbing?
- MarketBeat Week in Review – 10/19 – 10/23
- Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.
